An Open-Label, Safety and Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naïve Patients With Cystinosis
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2017
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Cystinosis
- Focus Pharmacodynamics; Registrational
- Sponsors Horizon Pharma USA; Raptor Pharmaceutical Inc
- 13 Feb 2017 Status changed from active, no longer recruiting to completed.
- 22 Oct 2015 Planned End Date changed from 1 Mar 2016 to 1 Nov 2016, according to ClinicalTrials.gov record.
- 22 Oct 2015 Planned primary completion date changed from 1 Mar 2016 to 1 Nov 2016, according to ClinicalTrials.gov record.